Examples of Medications in Different Blood Pressure Classes
The World Health Organization (WHO) recommends four main classes of antihypertensive medications as first-line treatment options: thiazide and thiazide-like diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and long-acting dihydropyridine calcium channel blockers. 1
Thiazide and Thiazide-like Diuretics
- Hydrochlorothiazide (HCTZ): Typically dosed at 12.5-25 mg daily, blocks sodium and chloride reabsorption in the distal tubule, increasing sodium and water excretion 2
- Chlorthalidone: 12.5-25 mg daily, preferred over other thiazides due to longer half-life and proven cardiovascular disease reduction 3
- Indapamide: Associated with fewer metabolic side effects compared to HCTZ 4
Angiotensin-Converting Enzyme (ACE) Inhibitors
- Lisinopril: Initial dose 10 mg once daily, usual maintenance dose 20-40 mg daily 5
- Enalapril: 5-40 mg daily, particularly beneficial in patients with diabetes, heart failure, and chronic kidney disease 3
- Perindopril: Shown to reduce cardiovascular events in patients with stable coronary artery disease 1
- Ramipril: Demonstrated reduction in cardiovascular events in high-risk patients 1
- Benazepril: Often combined with diuretics for enhanced blood pressure control 4
Angiotensin Receptor Blockers (ARBs)
- Losartan: 50-100 mg daily, shown in the LIFE study to reduce cardiovascular events better than beta-blockers in certain populations 1, 3
- Valsartan: Demonstrated benefit in heart failure patients 1
- Candesartan: Effective in heart failure management 1
Calcium Channel Blockers (CCBs)
Dihydropyridine CCBs
- Amlodipine: 2.5-10 mg daily, particularly effective in Black patients and elderly patients with isolated systolic hypertension 1, 3
- Felodipine: 2.5-20 mg daily 1
- Nifedipine (long-acting): 30-60 mg daily 1
- Nisoldipine: 10-40 mg daily 1
Non-dihydropyridine CCBs
- Diltiazem extended release: 180-420 mg daily 1
- Verapamil: 120-480 mg daily in various formulations 1
- Note: These should be avoided in patients with heart failure due to negative inotropic properties 1
Beta-Blockers
- Metoprolol: Effective antihypertensive agent at 100-450 mg daily, particularly useful when hypertension coexists with angina or post-myocardial infarction 6
- Carvedilol: Shown to improve outcomes in heart failure patients 1
- Bisoprolol: Beneficial in heart failure management 1
- Note: Beta-blockers are no longer considered first-line for uncomplicated hypertension due to reduced stroke prevention compared to other agents 3
Other Antihypertensive Classes
Alpha-1 Blockers
- Doxazosin: 1-16 mg daily 1
- Prazosin: 2-20 mg daily in divided doses 1
- Terazosin: 1-20 mg daily 1
- Caution: Should be avoided in heart failure patients due to increased risk 1
Central Alpha-2 Agonists
- Clonidine: 0.1-0.8 mg daily in divided doses 1
- Note: Moxonidine (same class) increased mortality in heart failure, so clonidine should be used cautiously 1
Direct Vasodilators
Combination Therapy Considerations
- More than 70% of adults treated for primary hypertension will eventually require at least two antihypertensive agents 7
- Effective two-drug combinations include:
- Important: ACE inhibitors and ARBs should not be used simultaneously as this increases adverse effects without additional benefit 3, 7
Special Population Considerations
- Black patients: Initial therapy should include a thiazide-type diuretic or CCB 3, 7
- Diabetes patients: ACE inhibitors or ARBs are preferred, especially with albuminuria 1, 3
- Chronic kidney disease patients: ACE inhibitors or ARBs are preferred, particularly with albuminuria ≥300 mg/day 1, 3
- Heart failure patients: Diuretics, ACE inhibitors (or ARBs), beta-blockers, and aldosterone receptor antagonists are recommended 1
Common Pitfalls to Avoid
- Combining ACE inhibitors with ARBs increases adverse effects without additional benefit 3
- Non-dihydropyridine CCBs (verapamil, diltiazem) should be avoided in heart failure patients 1
- Alpha blockers like doxazosin should be used only if other agents are inadequate for blood pressure control 1
- Short-acting CCBs are not recommended for hypertension management 1